Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047203 · ClinicalTrials.gov registry record · Phase 2
Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00047203: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00047203 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047203, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of flavopiridol in treating patients who have relapsed or refractory multiple myeloma
Interventions
- DRUG alvocidib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2002-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047203
The ClinicalTrials.gov registry entry for NCT00047203 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which alvocidib is the first listed.
NCT00047203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047203 about?
NCT00047203 is a clinical study titled "Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma". Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase II trial to study the effectiveness of flavopiridol in treating patients who have relapsed or refractory multiple myeloma
What is the current status of trial NCT00047203?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2002-09.
What interventions are being tested in trial NCT00047203?
The interventions under investigation include: alvocidib (DRUG).
Who is sponsoring clinical trial NCT00047203?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.